Discover 1,359 paid clinical trials in Athens, Georgia. Search by condition or phase to find a research study near you that matches your needs across various therapeutic areas.
Filter
2
Filter results
Results: 1,359
Symbiotic-Lung-10: A Study to Learn About PF-08634404 Alone or in Combination in Early-stage or Locally Advanced NSCLC
for
Carcinoma, Non-Small-Cell Lung, Lung Cancer (NSCLC),
Location: Athens GA, Knoxville TN, Huntsville AL, New Lenox IL,
Sponsor: Pfizer
Sex: All
Age: 18+
Code: NCT07489066
Phase2, Recruiting
BGB-43395 Plus Letrozole Versus CDK4/6i Plus Letrozole for Patients With Advanced or Metastatic HR+/HER2- Breast Cancer Who Have Not Received Prior Treatment for Advanced or Metastatic Disease
A Study to Evaluate the Efficacy of Pumitamig Versus Pembrolizumab in Participants With Previously Untreated Advanced Non-Small Cell Lung Cancer and PD-L1 ≥ 50%. (ROSETTA Lung-202)
A Study to Learn About the Medicine Ponsegromab in Adults With Cancer of the Pancreas Which Has Spread and Caused Significant Body Weight Loss and Fatigue
Get alerts for new trials in your area by subscribing now
Open-label Study Comparing AAA817 Versus Standard of Care in the Treatment of Previously Treated PSMA-positive mCRPC Adults Who Have Disease Progressed on or After [177Lu]Lu-PSMA Targeted Therapy
for
Prostate Cancer
Location: Athens GA, Atlanta GA, Myrtle Beach SC, Roanoke VA,
Sponsor: Novartis Pharmaceuticals
Sex: Male
Age: 18 - 70+
Code: NCT06780670
Phase2, Phase3, Recruiting
Study of Sacituzumab Govitecan-hziy and Pembrolizumab Versus Treatment of Physician's Choice in Patients With Triple Negative Breast Cancer Who Have Residual Invasive Disease After Surgery and Neoadjuvant Therapy (ASCENT-05/AFT-65 OptimICE-RD/GBG 119/NSABP B-63)
for
Triple Negative Breast Cancer
Location: Athens GA, Atlanta GA, Marietta GA, Greenville SC,
Sponsor: Gilead Sciences
Sex: All
Age: 18+
Code: NCT05633654
Phase3, Recruiting
A Study to Evaluate Zilovertamab Vedotin (MK-2140) Combination With Rituximab Plus Cyclophosphamide, Doxorubicin, and Prednisone (R-CHP) Versus Rituximab Plus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone (R-CHOP) in Participants With Previously Untreated DLBCL (MK-2140-010)
Study of Olomorasib (LY3537982) in Combination With Standard of Care in Participants With Resected or Unresectable KRAS G12C-mutant Non-Small Cell Lung Cancer
for
Carcinoma, Non-Small-Cell Lung
Location: Athens GA, Atlanta GA, West Columbia SC, Chattanooga TN,
Sponsor: Eli Lilly and Company
Sex: All
Age: 18+
Code: NCT06890598
Phase3, Recruiting
Targeted Treatment for Advanced Non-Small Cell Lung Cancer That Has a MET Exon 14 Skipping Gene Change (An Expanded Lung-MAP Treatment Trial)
for
Recurrent Lung Non-Small Cell Carcinoma,
Location: Athens GA, Gainesville GA, Anderson SC, Pinehurst NC,
Sponsor: SWOG Cancer Research Network
Sex: All
Age: 0+
Code: NCT06031688
Phase2, Recruiting
A Study to Evaluate Mezigdomide, Bortezomib and Dexamethasone (MEZIVd) Versus Pomalidomide, Bortezomib and Dexamethasone (PVd) in Participants With Relapsed or Refractory Multiple Myeloma (RRMM)
for
Relapsed or Refractory Multiple Myeloma
Location: Athens GA, Durham NC, Roanoke VA, Cincinnati OH,
Sponsor: Celgene
Sex: All
Age: 18+
Code: NCT05519085
Phase3, Recruiting
A Clinical Study to Find the Optimal Dose of an Investigational Treatment Called BNT323 When Used in Combination With Another Investigational Treatment, BNT327, and to Test if That Combination Treatment is Safe and Beneficial for Patients With Advanced Breast Cancer
for
Locally Advanced Breast Cancer, Unresectable Breast Carcinoma,
Location: Athens GA, Atlanta GA, Nashville TN,
Sponsor: BioNTech SE
Sex: All
Age: 18+
Code: NCT06827236
Phase1, Phase2, Recruiting
A Study of First-Line Olomorasib (LY3537982) and Pembrolizumab With or Without Chemotherapy in Patients With Advanced KRAS G12C-Mutant Non-small Cell Lung Cancer
Location: Athens GA, Atlanta GA, Greenville SC, West Columbia SC,
Sponsor: Eli Lilly and Company
Sex: All
Age: 18+
Code: NCT06119581
Phase3, Recruiting
Phase 2 Trial of Adagrasib Monotherapy and in Combination With Pembrolizumab and a Phase 3 Trial of Adagrasib in Combination in Patients With a KRAS G12C Mutation KRYSTAL-7